CN
CNBX.US Cannabics Pharmaceuticals Inc
- Market cap
- USD 161K
- P/E
- -
- P/B
- 20.39x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to May 2026.
Is CNBX.US undervalued?
Graham numberThe Graham number of Cannabics Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cannabics Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Cannabics Pharmaceuticals Inc yet.
Cannabics Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cannabics Pharmaceuticals Inc
CNBX Pharmaceuticals Inc., a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the local treatment of lateral spreading, or s…
Full company profileCannabics Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to May 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cannabics Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 113K | 5.68K | 9.60K | 9.84K | 7.16K | 0.00 | 30.0K | 410K | 130K | 0.00 | 0.00 |
| Gross Profit | 113K | -1.34K | 9.60K | 9.84K | 7.16K | -221K | -169K | 410K | 130K | - | - |
| Operating Income | -281K | -1.85M | -3.81M | -3.30M | -3.04M | -2.60M | -2.95M | -931K | -583K | -272K | -400K |
| EBITDA | -278K | -1.92M | -3.72M | 1.34M | -7.24M | -2.91M | -3.52M | -3.55M | -603K | -274K | -400K |
| Net Income | -307K | -1.93M | -3.78M | 1.13M | -7.47M | -3.19M | -3.72M | -3.71M | -695K | -314K | -416K |
| EPS | -0.36 | -2.10 | -3.76 | 1.03 | -6.66 | -2.77 | -3.04 | -0.42 | -0.02 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 23.7K | 3.64M | 3.18M | 15.2M | 2.22M | 3.08M | 811K | 499K | 31.4K | 18.4K | 12.8K |
| Total Liabilities | 491K | 699K | 539K | 439K | 455K | 1.27M | 2.44M | 2.52M | 2.51M | 2.51M | 2.67M |
| Shareholders' Equity | -467K | 2.94M | 2.65M | 14.7M | 1.76M | 1.81M | -1.63M | -2.02M | -2.48M | -2.50M | -2.66M |
| Cash & Short-term Investments | 0.00 | 3.37M | 1.39M | 3.52M | 778K | 1.39M | 118K | 130K | 26.4K | 15.1K | 9.49K |
| Total Debt | - | - | - | - | - | 872K | 1.76M | 1.34M | 1.30M | 1.20M | 120K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -120K | -864K | -1.97M | -3.09M | -2.77M | -2.49M | -1.68M | -113K | -244K | -171K | -167K |
| Capital Expenditure | 126K | 126K | 942K | 217K | 75.7K | 943.00 | 1.66K | 1.00 | 1.20K | 0.00 | 4.00 |
| Free Cash Flow | - | -989K | -2.92M | -3.31M | -2.85M | -2.49M | -1.68M | -113K | -245K | -171K | -167K |
| Ratios | |||||||||||
| ROE | - | -65.8% | -142.8% | 7.7% | -423.2% | -176.9% | - | - | - | - | - |
| ROA | -1,294.5% | -53.2% | -118.6% | 7.5% | -336.5% | -103.7% | -459.0% | -743.4% | -2,214.6% | -1,703.0% | -3,251.1% |
| Net Profit Margin | -272.9% | -34,022.5% | -39,335.7% | 11,510.7% | -104,331.4% | - | -12,427.4% | -904.5% | -534.3% | - | - |
| Debt to Equity | - | - | - | - | - | 0.48x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cannabics Pharmaceuticals Inc dividends
Cannabics Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:120 on May 12, 2022.
Who owns Cannabics Pharmaceuticals Inc
- Insiders 0.05%
- Institutions 4.98%
- Public & others 94.97%
- Shares outstanding 1.61B
- Free float 1.61B
Cannabics Pharmaceuticals Inc company profile
- Company name
- Cannabics Pharmaceuticals Inc
- Ticker
- CNBX.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1
- Fiscal year end
- August
- Address
- #3 Bethesda Metro Center, Bethesda, MD, United States, 20814
- Phone
- 877 424 2429
- Website
- cnbxpharma.com
About Cannabics Pharmaceuticals Inc
CNBX Pharmaceuticals Inc., a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the local treatment of lateral spreading, or sessile, colorectal polyps during colonoscopy, BRST-33 for the treatment of breast cancer, MLN-33 for the treatment of melanoma, and PRST-33 for the treatment of prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland.
Cannabics Pharmaceuticals Inc management
9- Mr. Gabriel YarivPresident, COO & Executive Chairman · born 1976
- Mr. Eyal BaradCo-Founder, CEO & Director · born 1965
- Mr. Uri Ben-Or CPA, M.B.A.Chief Financial Officer · born 1970
- Dr. Sigalit Ariely-Portnoy Ph.D.Senior Advisor of Regulation, Validation & Quality and Member of Advisory Board · born 1964
- Dr. Tal Mofkadi Ph.D.Financial Advisor & Member of Advisory Board
- Mr. Yasha BorsteinChief Data Officer · born 1963
- Dr. Yaakov WaksmanHead of Cannabidiol Research · born 1952
- Dr. Ilya Reznik M.D.Head of Neuropsychiatry Development
- Dr. Lior EshdatMember of Scientific Advisory Board & VP of IP